Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device

• Status: Terminated
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals

Criteria

Inclusion Criteria:

• Patient with growth hormone deficiency,

1. Diagnosis of growth hormone deficiency proven by appropriate exploration

2. Size ≤ -2 Standard Deviation (SD) according to the French references

3. Growth velocity in the previous year inferior to the normal for age (-1SD) or < 4cm/year

• Growth deficiency due to Turner's syndrome

1. Turner's syndrome confirmed by a karyotype

2. Patient's size ≤ -2 SD according to the French references

3. Bone age < 12 years

• Patient who require a minimum of 18 months of treatment.

Exclusion Criteria:

• There are no exclusion criteria except the contraindication for Zomacton® 10 mg